In a relatively classic scenario, established technologies have seen a loss of their once-premium pricing while emerging technologies are able to command an increasing premium as reward for their sophistication.
The worldwide coronary stent market is following the predicted course. Bare metal stents have been on the market for more than a decade and have, for [...]
In medical technology development, there are perennially long-shot technologies being pursued for their ability to make an order of magnitude shift in treatment. This, of course, seems to be the thrust of a majority of biotechnology development, which seeks to provide cures where only palliative treatments (drug or device) currently exist, such as in gene [...]
The improvements in stent flexibility and biocompatibility have lead to the conclusion by Dr. Mitchell Krucoff that second-generation drug eluting-stents, such as Abbott's Xience stent, result in an improved ability to prevent restenosis following angioplasty and stent implantation. See an excerpt from India's pharmabiz.com (which also highlights the market potential for coronary stents in India):
Newer [...]
The global market for stents in the treatment coronary artery disease, while dominated by drug-eluting stents, continues to also be comprised of a diversity of stent technologies. The market is evolving steadily as manufacturers aggressively seek optimal anti-restenosis, characterized by the goal of low rates of repeat revascularization.
As with many medical technologies, prices, availability in [...]
Coronary stent technology development trends include the stimulation of vessel wall healing following revascularization.
OrbusNeich has developed its "Genous", a patented endothelial progenitor cell (EPC) capture technology designed and shown to promote the accelerated natural healing of the vessel wall following stenting.
See link on OrbusNeich Genous recent data.
The MedMarket Diligence report #C245 covers the global [...]
PRLog (Press Release) – Sep 09, 2009 – The global market for coronary stents is owned largely by drug-eluting stents (DES), but the size of the patient pool, the drive for lowered cost, ever-increased efficacy and less trauma are spawning the development of multiple new technologies in coronary stents and competitive anti-restenosis technologies. The global [...]
In my regular review of industry press releases, patents (and applications), peer-reviewed journals and other medtech sources, I am occasionally struck by an article or paper that I find compellingly succinct or clear or detailed — or all of the above. The clinical background and technology development of coronary drug-eluting stents are areas I [...]
Translation: Drug-eluting stents are to bare metal stents as bare metal stents were to percutaneous transluminal coronary angioplasty alone.
In the September 1 post on the meta-analysis by researchers at Tuft Medical Center, we noted the overall findings in general terms of the value of drug-eluting stents compared to bare metal stents. It is worthwhile to provide [...]
In a extensive meta-analysis of data from 12 clinical trials over nine years and 4,902 patients, researchers at the Division of Clinical Decision Making, Informatics and Telemedicine at Tufts Medical Center distilled the common thread of findings comparing drug-eluting with bare metal stents. The conclusion, succinctly, is:
"Coronary drug-eluting stents significantly reduced the rates of restenosis [...]
The global coronary stent market faces continued growth, development and competition from a wide range of technology types and competitors. The market is detailed in a new report from MedMarket Diligence.
FOR IMMEDIATE RELEASE
PRLog (Press Release) – Aug 31, 2009 – Since the advent of coronary stents, followed by the emergence of drug eluting stents, the [...]
Contact:
